Farallon Capital Management, L.L.C. and thirteen associated individuals filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing a shared position of 950,000 shares of Enanta Pharmaceuticals Inc common stock as of September 30, 2026.

Key Highlights

  • Filing event date: The statement was triggered by an event occurring on September 30, 2026.
  • Amendment number: This is Amendment No. 9 to the reporting group's beneficial ownership statement for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
  • Aggregate beneficial ownership: Each reporting person lists 950,000 shares of common stock, par value $0.01 per share, with CUSIP 29251M106.
  • Percentage of class: The 950,000 shares represent 3.3% of Enanta's outstanding common stock, according to the filing.
  • Voting and dispositive power: All 950,000 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.00.
  • Reporting entity type: Farallon Capital Management, L.L.C. is classified as an investment adviser (IA) and other organization (OO); the thirteen named individuals are classified as holding companies (HC) and individuals (IN).

Farallon Capital Management's Shared Position in Enanta Pharmaceuticals

According to the filing, Farallon Capital Management, L.L.C., a Delaware-organized investment adviser, together with thirteen named individuals, collectively reported beneficial ownership of 950,000 shares of Enanta Pharmaceuticals Inc common stock. Enanta Pharmaceuticals is a clinical-stage biopharmaceutical company whose common shares trade on NASDAQ:ENTA. The statement covers shares with a par value of $0.01 per share under CUSIP number 29251M106.

The filing reports that none of the fourteen reporting persons hold any sole voting or sole dispositive power over the shares. Instead, each of the fourteen reporting persons, including Farallon Capital Management, L.L.C. and individuals such as Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Varun N. Gehani, Nicolas Giauque, Avner A. Husen, David T. Kim, Michael G. Linn, Patrick (Cheng) Luo, Thomas G. Roberts Jr., Edric C. Saito, Daniel S. Short, and Andrew J. M. Spokes, each report shared voting power and shared dispositive power of 950,000 shares.

The aggregate amount beneficially owned by each reporting person is stated as 950,000 shares, representing 3.3% of the class. The filing is designated Amendment No. 9, indicating that prior beneficial ownership statements covering Enanta Pharmaceuticals common stock have been submitted by this reporting group on at least eight previous occasions. The citizenship or place of organization of the individual reporting persons spans the United States, France, China, and the United Kingdom, according to the filing.

What Was Disclosed

The filing disclosed that Farallon Capital Management, L.L.C. and thirteen associated individuals each reported beneficial ownership of 950,000 shares, equaling 3.3% of Enanta Pharmaceuticals Inc common stock, with all shares held under shared voting and shared dispositive power as of September 30, 2026.